Cholenak0.5%+0.1%+0.393%

Cholenak is an electrolyte and fluid replacement product used under medical supervision. Its use is classified by strength of evidence below.

Established / Approved Uses

• Replacement and maintenance of fluid and electrolytes (sodium, potassium, and acetate/bicarbonate) in patients with dehydration or electrolyte deficits, typically as an intravenous infusion given in a hospital or clinical setting.
• Correction of mild-to-moderate metabolic acidosis, where the acetate component is metabolized to bicarbonate to help restore acid-base balance.

Adjunct / Supportive Use

• As part of overall fluid management in surgical, postoperative, or critically ill patients who require electrolyte support alongside other therapies, as determined by the treating physician.

The exact formulation and route (intravenous solution, or other electrolyte-replacement product) depend on the specific brand and pack; intravenous forms of Cholenak must only be administered by trained medical personnel in a facility equipped to monitor fluid and electrolyte status.

Sodium Chloride + Potassium Chloride + Sodium Acetate combines three electrolyte components: sodium chloride, potassium chloride, and sodium acetate. The exact strength/concentration of each component (e.g., mEq or mg per mL, or per sachet/tablet for oral-type products) varies by brand and pack size; refer to the specific product label for exact composition.

Cholenak is a fixed combination electrolyte replacement product that supplies sodium, potassium, chloride, and acetate ions. It is used to correct or prevent depletion of these electrolytes and to help normalize acid-base status, since the acetate component is converted in the body to bicarbonate, an alkalinizing buffer. Cholenak is most commonly formulated as a sterile intravenous solution, though other electrolyte-replacement dosage forms may exist depending on the manufacturer.

Cholenak belongs to the therapeutic class of electrolyte and fluid replenishers (intravenous electrolyte solutions used for fluid and electrolyte replacement/maintenance therapy).

Sodium Chloride + Potassium Chloride + Sodium Acetate restores physiologic concentrations of sodium, potassium, and chloride ions, which are essential for maintaining osmotic pressure, fluid distribution between body compartments, neuromuscular function, and acid-base balance.

• Sodium and chloride are the principal extracellular ions responsible for maintaining plasma osmolality and circulating fluid volume.
• Potassium is the principal intracellular cation, essential for normal cardiac, skeletal, and smooth muscle function and for nerve conduction.
• Sodium acetate is metabolized primarily in the liver to bicarbonate, which acts as an alkalinizing agent to help correct mild metabolic acidosis without contributing an additional chloride load.

When administered intravenously, Sodium Chloride + Potassium Chloride + Sodium Acetate is distributed throughout the extracellular fluid compartment; excess electrolytes are eliminated mainly by the kidneys.

Cholenak intravenous solutions are for intravenous infusion only and must be administered by trained medical personnel in a hospital or clinical setting equipped for monitoring.

• Inspect the container visually for particulate matter, discoloration, or damage before use; do not use if the solution is not clear or if the container is leaking.
• Administer using aseptic technique via a calibrated infusion pump/device to control the rate accurately.
• Do not add other medications to the container unless compatibility has been confirmed.
• Monitor the infusion site for signs of extravasation, and monitor the patient's fluid balance, vital signs, and serum electrolytes throughout therapy.

Clinically significant interactions with Cholenak mainly relate to its potassium and sodium content:

• Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), ACE inhibitors, and angiotensin receptor blockers: co-administration with Cholenak increases the risk of hyperkalemia; potassium levels should be monitored closely.
• Corticosteroids and drugs causing sodium retention: may add to the sodium/fluid load delivered by Cholenak, increasing the risk of fluid overload and edema.
• Cardiac glycosides (e.g., digoxin): rapid shifts in serum potassium caused by inappropriate use of Cholenak can increase the risk of digoxin-related cardiac arrhythmias.
• Lithium: changes in sodium balance produced by Cholenak can alter renal lithium clearance and lithium blood levels.

Adverse effects with Cholenak are generally related to the rate/volume of administration or to underlying organ dysfunction rather than to a direct drug toxicity:

• Infusion-site reactions: pain, redness, or phlebitis at the injection site.
• Fluid overload: edema, shortness of breath, worsening of heart failure if administered too rapidly or in excessive volume (see Precautions).
• Electrolyte disturbances: hyperkalemia, hypernatremia, or metabolic alkalosis, particularly with excessive or inappropriate use.
• Rarely, hypersensitivity-type reactions (rash, chills, fever).

Cholenak should be used in pregnancy only if clearly needed for correction of a genuine fluid/electrolyte deficit, and only under close medical supervision, as fluid and electrolyte balance is important for both mother and fetus; the potential benefit should justify any potential risk, and a physician should individualize the fluid/electrolyte prescription. Similarly, in breastfeeding women, Cholenak may be used when clinically indicated for correction of fluid/electrolyte imbalance, under medical supervision, as physiologic electrolyte replacement is not expected to pose a specific risk to the breastfed infant when appropriately dosed and monitored; consult a physician before use.

Cholenak must be administered only under medical supervision, with the following precautions:

• Fluid overload: use with caution in patients with congestive heart failure, severe renal impairment, or hepatic impairment (e.g., cirrhosis with ascites), as these patients are at higher risk of circulatory overload and edema; infuse slowly and monitor closely.
• Electrolyte imbalance: excessive or inappropriate use of Cholenak can cause hyperkalemia, hypernatremia, or metabolic alkalosis; serum electrolytes (particularly potassium), acid-base status, and fluid balance should be monitored regularly during therapy.
• Renal function: use cautiously in any degree of renal impairment because of reduced capacity to excrete potassium and sodium.
• Intravenous forms require administration by trained medical personnel with appropriate monitoring equipment; do not self-administer.

Overdosage or too-rapid administration of Cholenak can cause fluid overload, hyperkalemia (which can lead to dangerous cardiac arrhythmias), hypernatremia, and metabolic alkalosis. Symptoms may include swelling, difficulty breathing, muscle weakness, irregular heartbeat, or confusion. If overdose is suspected, the infusion should be stopped immediately and the patient should receive emergency medical attention; contact a physician, hospital emergency department, or poison control center right away. Management is supportive and is directed by a physician based on the specific electrolyte and fluid abnormalities found (do not attempt home treatment).

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children. Do not use if the container is damaged, the seal is broken, or the solution is discolored or contains visible particles.

Renal Impairment

Use Cholenak with caution and under close monitoring; reduced renal excretion increases the risk of potassium and fluid accumulation (see Contraindications for severe renal impairment with oliguria/anuria).

Hepatic Impairment

Use with caution; patients with hepatic impairment (e.g., cirrhosis with ascites) are more susceptible to fluid overload and sodium retention.

Cardiac Disease

Use with caution in patients with congestive heart failure or other conditions predisposing to fluid overload; infuse slowly with close monitoring.

Elderly

Elderly patients often have reduced renal and cardiac reserve; use Cholenak cautiously with close monitoring of fluid balance and electrolytes.

The duration of Cholenak therapy is individualized and determined by the treating physician based on the severity of the fluid/electrolyte deficit and the patient's response, as guided by repeat clinical assessment and laboratory testing. Treatment is generally continued only until fluid and electrolyte balance is restored to a safe, stable level and is then discontinued or tapered as directed by the physician.

Sodium Chloride + Potassium Chloride + Sodium Acetate falls under the drug class of intravenous electrolyte and fluid replacement solutions, used for maintenance and replacement fluid therapy.

Sodium Chloride + Potassium Chloride + Sodium Acetate works by directly replenishing depleted extracellular electrolytes. Sodium and chloride restore extracellular fluid volume and osmotic balance; potassium restores intracellular potassium stores essential for cardiac and neuromuscular function; and sodium acetate is metabolized by the liver into bicarbonate, which buffers excess hydrogen ions and helps correct metabolic acidosis without adding extra chloride load.

Cholenak may be used in pediatric patients, including infants, for fluid and electrolyte replacement when clinically indicated, but dosing must be individualized based on body weight, age, and clinical/laboratory status by a physician experienced in pediatric fluid management. Neonates and young infants require particularly close monitoring of fluid balance and serum electrolytes because of their limited capacity to handle fluid and electrolyte loads. Safety and efficacy of specific commercial formulations of Cholenak in children should be confirmed against the individual product's labeling, as not all formulations are studied in every pediatric age group.